Background Identifi cation of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine the eff ectiveness of diff erent vaccine strategies to block virus shedding. We used samples from a clinical trial of diff erent vaccination schedules to measure intestinal immunity as judged by neutralisation of virus and virus-specifi c IgA in stools.
Introduction
As the spread of poliovirus is progressively constrained both geographically and in circulating lineages, crucial decisions are being made about future vaccination strategies to achieve and sustain the fi nal eradication of poliomyelitis. 1, 2 These plans include elimination of the type 2 component of the trivalent oral attenuated poliovirus vaccine (tOPV), as recommended by the Strategic Advisory Group of Experts on Immunization, and replacement with bivalent oral poliovirus vaccine (bOPV) accompanied by the introduction of at least one dose of inactivated polio vaccine (IPV) into the regimen, enhanced environmental surveillance, and the eventual elimination of any use of the live oral poliovirus vaccines (OPVs) in immunisation programmes. The cessation of the use of OPV type 2 and the substitution of at least one dose of IPV occurred as planned globally in April and May, 2016.
These recommendations, made in 2012, were based on expert opinion and the epidemiological situation of poliovirus transmission, but no immunogenicity and safety data for bOPV-IPV routine immunisation schedules compared with tOPV immunisation sche dules-particularly the eff ects on intestinal immunity against type 2 Sabin virus-were available to inform them. The IPV and OPV both prevent paralytic poliomyelits in the vaccine recipient, and both have interrupted transmission, although the impact of IPV on transmission has largely been reported in developed countries. Mucosal immunity is presumed to have a key role in limitation of enteric and pharyngeal infection with poliovirus, and hence could be crucial in diminishing the effi ciency of transmission. Yet the notion that IPV will be central to maintenance of eradication is based on the potential development of vaccine-associated paralytic polio in OPV recipients, 3 chronic OPV infection in immunodefi cient vaccine recipients, 4 and circulation of vaccine-derived polioviruses. 5 The comparative ability of OPV and IPV to induce mucosal immunity has been explored since the early days of polio research. Ouchterlony double diff usion plates were used to show that OPV induces enteric IgA, whereas IPV does not, unless preceded by OPV. 6, 7 The concept that mucosal immunity was dependent on previous vaccination with OPV was supported by challenging IPV and OPV recipients with OPV. 8, 9 Combination of OPV and IPV to broaden immunogenicity was introduced 18 years ago. 10 More recently, investigators in Cuba, 11 India, 12, 13 Bangladesh, 14 Chile, 15 and four Latin American countries in the Fighting Infectious Diseases in Emerging Countries (FIDEC) 16 consortium have used challenge with either monovalent OPV (mOPV) or tOPV as a measure of the immuno genicity and protection aff orded by previous immuni sation with OPV or IPV, either individually or in combination.
Anticipatory studies of the mechanisms that limit poliovirus replication are crucial to inform decisions by the Global Polio Eradication Initiative to move from OPV to IPV. Studies of mucosal immunity induced by OPV, IPV, and mixed schedules will defi ne the best strategy, not only for prevention of paralytic disease, but also for the true eradication of all circulating poliovirus. The lack of defi nitive information in this area was shown in 2013 by leaders in the fi eld, who expressed very diverse views on the eff ectiveness of IPV in limiting virus replication at mucosal sites and thus preventing transmission. 17 Previous studies have yet to link mucosal responses measured by current immunological techniques to the type of vaccine given or to virus shedding on challenge. To address this gap in knowledge, we measured polio-specifi c mucosal IgA responses and virus-neutralising capacity of stool samples and correlated these fi ndings with vaccine regimen and virus shedding on OPV challenge.
Methods

Study design and participants
The FIDEC study (NCT 01831050) was designed to explore the safety, immunogenicity, and protective effi cacy of combinations of IPV and OPV in anticipation of the elimination of type 2 OPV from global vaccination use. Infants in the study were randomly assigned to nine groups to assess the effi cacy of two schedules of bOPV and IPV and challenge with monovalent type 2 OPV. Stool samples were collected during the FIDEC trial as reported 16 and provided to us so that we could analyse mucosal responses. Because of the large number of samples collected and the complexity of the analyses, stool specimens were specifi cally selected from three non-overlapping groups of particular scientifi c interest: the bOPV control group, in which 210 infants received bOPV (serotypes 1 and 3) at 6, 10, and 14 weeks, followed by challenge with mOPV type 2 at 18 weeks; the tOPV control group, in which 100 infants received tOPV at 6, 10, and 14 weeks, with mOPV type 2 challenge at 18 weeks; and the bOPV-IPV group, in which 210 infants received bOPV at 6, 10, and 14 weeks and one dose of the IPV at 14 weeks, with mOPV type 2 challenge at 18 weeks. Other groups in the parent study that were not analysed in ours received either two doses of IPV in addition to OPV or were challenged at 40 weeks rather than 18 weeks with mOPV type 2, or both. 16 The study was approved by the Dartmouth College Committee for the Protection of Human Subjects and by
Research in context
Evidence before this study We searched PubMed with the term "polio mucosal immunity" for articles published in English between Jan 31, 1975, and Dec 31, 2015. We identifi ed several studies in which virus shedding after oral challenge was used as a surrogate for mucosal immunity, but very few in which investigators attempted to measure IgA specifi c antibody in the stool and none in which neutralising antibody in the stool was successfully measure and correlated with virus recovery on oral poliovirus challenge.
Added value of this study
We present the fi rst data showing the impact of trivalent attenuated oral poliovirus vaccine (tOPV), bivalent oral poliovirus vaccine (bOPV), and a combination of bOPV and inactivated poliovirus vaccine (IPV) on intestinal immunity against type 2 poliovirus when administered according to the Expanded Program on Immunization schedule and document the eff ect of that immunity on subsequent challenge with the proposed outbreak response tool of the future, monovalent oral poliovirus vaccine (mOPV) type 2. Immunity is measured by restriction of virus shedding, neutralisation of virus in the stool, and mOPV type 2 IgA specifi c antibody. The correlations of each with the other strengthens the concept that we now have tools to measure mucosal immunity and predict the eff ectiveness of a vaccine regimen in limiting outbreaks as we approach polio eradication.
Implications of the available evidence
Our novel data have direct and immediate global policy implications and point to the unique ability of tOPV to stimulate mucosal immunity, the dissociation of serum and mucosal antibody responses, and the crucial role of mucosal immunity in preventing infection on an mOPV type 2 challenge. They provide support for the global withdrawal of type-2-containing oral poliovirus vaccines to eliminate the only source of paralytic disease caused by this serotype, and show that, although IPV is highly protective against paralytic disease in the individual vaccinee, it has only a small eff ect on subsequent virus shedding and thus could allow a continued train of transmission. Our data will help national, regional, and global policy makers to develop public health strategies to achieve and sustain polio eradication in the near term and long term.
the FIDEC ethical review process. Provision had been made in the initial consent for future studies and it was judged unnecessary to reconsent the volunteers.
Procedures
The FIDEC study was implemented in four countries (Colombia, Dominican Republic, Guatemala, and Panama). We determined that analysis of all samples from two of these countries-Dominican Republic and Guatemala-would yield statistically meaningful data for our study. Because limited inter-country diff erences were noted, results from the two countries were pooled for all data analyses.
Stool samples (5-10 g) were collected and frozen in aliquots in the country of origin. Samples were then shipped frozen to the Geisel School of Medicine at Dartmouth (Hanover, NH, USA). Assays quantifying virus neutralisation titres and IgA concentrations in stools were done at Dartmouth as previously reported. 18, 19 Mucosal immunity was measured by in-vitro neutralisation of a type 2 polio pseudovirus (PV2). Neutralisation titres and total and polio-type-specifi c IgG and IgA concentrations in stools were assessed in samples collected before challenge and 2 weeks after challenge from all subjects. The same measurements were done on samples collected weekly for the fi rst 4 weeks after challenge from 49 randomly chosen parti cipants by the Dartmouth team (before any know ledge of group allocation). Serum neutralisation titres before challenge and a week later, and virus shedding weekly after challenge, were measured at the Polio and Picornavirus Laboratory Branch of the Centers for Disease Control and Prevention (Atlanta, GA, USA). Vaccine group assignment, serum neutralisation titres, and virus shedding were unblinded to the Dartmouth study team after completion of sample testing and data sharing.
Statistical analyses
Diff erences in the proportions of children with virus shedding and with measurable PV2 mucosal neutralisation were compared across the three vaccine regimen groups with Pearson's χ² test. We used ANOVA to compare the geometric means of observed virus shedding, stool and serum neutralisation titres, and mucosal IgA concentrations across the three groups. Diff erences between pairs of groups and between visits within each group were compared with Tukey's honest signifi cant diff erence method-a simultaneous com parison of all pairwise means that identifi es diff erences between two means that are greater than the expected SE and is robust when sample sizes are unequal between groups. Differences were deemed signifi cant and p values reported when p was less than 0·05.
We used Spearman's rank correlation coeffi cients to examine correlations between shedding 1 week after type 2 mOPV challenge and poliovirus-type-specifi c serum and stool neutralisation titres and mucosal IgA concentrations at the time of challenge. We plotted the median (IQR) concen trations of each y variable against the mean for each third of the x variables, which allowed us to assess the shape of any correlation without assuming linearity a priori.
Role of the funding source
ASB is an employee of the study funder, and was involved in study design, data interpretation, and writing of the report. The funder had no role in data collection. All authors had full access to all the data in the study and share fi nal responsibility for the decision to submit for publication.
Results
In total, 586 samples were analysed from 210 infants given bOPV (n=85), tOPV (n=38), or bOPV-IPV (n=87), which represented approximately 40% of the children in each group. Mucosal immunity at the time of the mOPV type 2 challenge was signifi cantly associated with previous receipt of a vaccine containing the OPV type 2 component-ie, tOPV (fi gure 2). 14 (17%) of 82 individuals given bOPV also demonstrated mucosal PV2 neutralisation. One dose of IPV at 14 weeks (ie, in the bOPV-IPV group) was associated with measurable PV2 mucosal neutralisation in 21 (26%) of 82 infants, compared with 35 (42%) of 84 infants given bOPV (χ² [1, N=166]=4·79, p=0·03; fi gure 2). However, the additional dose of IPV had no signifi cant eff ect on the level of virus shedding compared with bOPV only (fi gure 1). At the time of mOPV type 2 challenge, type 1 polio pseudovirus neutralisation titres were similar in the three groups (data not shown).
Type-2-specifi c IgA concentrations measured in stool at the time of mOPV type 2 challenge were signifi cantly higher in infants given tOPV than in those receiving bOPV or bOPV-IPV (fi gure 3). Total IgG concentrations in the stool specimens were much lower than those of IgA; polio-strain-specifi c IgG antibodies were rarely detected (data not shown). Type-2-specifi c serum neutralisation titres were signifi cantly higher in infants who received a homologous type 2 vaccine (ie, those in the tOPV and bOPV-IPV groups) than in those who did not (fi gure 4).
Mucosal neutralising activity to PV2 developed rapidly after administration of the mOPV type 2 challenge in the bOPV and bOPV-IPV groups, reaching the levels of the tOPV group by 2 weeks after challenge (fi gure 5A). Mean IgA concentrations also increased in stool by 3-4 weeks after challenge in the bOPV and bOPV-IPV groups (fi gure 5B). By comparison, the vaccine regimen did not aff ect mucosal type-1-specifi c or type-3-specifi c IgA concentrations at the time of challenge, and these concentrations did not rise signifi cantly after mOPV type 2 challenge (data not shown).
Serum was obtained immediately before challenge and 1 week later under the assumption that this practice would capture a rapid anamnestic antibody response to vaccine priming. Serum neutralisation titres determined for the two available timepoints showed no signifi cant increase 1 week after challenge in the bOPV and bOPV-IPV groups (fi gure 5C). A comparison of both the mucosal and serum neutralisation titres 1 week after mOPV type 2 challenge showed equivalent responses in the bOPV and bOPV-IPV groups (fi gure 5A, 5C). Virus shedding was restricted 1 week after mOPV type 2 challenge in the tOPV group, which had received OPV type 2 as a component of the trivalent vaccine, compared with that in the bOPV and bOPV-IPV groups, neither of which had received OPV type 2 (fi gure 1; p<0·0001 for both). Similarly, signifi cantly higher mucosal neutralising responses to PV2 were noted in tOPV recipients at the time of mOVP type 2 challenge than were noted in those in the bOPV and bOPV-IPV groups (fi gure 2).
Separate analyses of the distribution of the type-2-specifi c serum and stool neutralisation responses at the time of mOPV type 2 challenge demonstrated a signifi cant relation between the heights of each response with the subsequent reduction in virus shedding 1 week after challenge (fi gures 6A, 6B). Concentrations of type-2-specifi c IgA measured at challenge did not correlate with subsequent virus shedding 1 week later (fi gure 6C).
A comparison of PV2-specifi c mucosal neutralisation titres with IgA concentrations in stools from the tOPV recipients at the time of challenge was signifi cant (p=0·043), with a weak correlation (r=0·33). Notably, by 2 weeks after mOPV type 2 challenge-when neutralising PV2-specifi c antibody responses in stool were signifi cantly increased in the bOPV and bOPV-IPV groups compared with those at time of challenge (fi gure 5A)-the correlation of mucosal neutralisation with type-2-specifi c IgA concentrations in stool was strong (fi gure 7B).
In infants shedding virus after mOPV type 2 challenge, we noted a signifi cant inverse correlation between the height of the mucosal response, as measured by both virus neutralising activity and IgA concentrations in stool, and the amount of virus concurrently shed 2 weeks after challenge (fi gure 7B). A correlation of virus shedding with mucosal IgA was not noted (fi gure 7C).
Discussion
Our results suggest that mucosal neutralising type-2-specifi c antibody, generated by previous serotype-specifi c OPV exposure, highly corresponds with resistance to challenge with mOPV type 2. Although type-2-specifi c serum neutralising antibody also in fl uenced the initial replication of mOPV type 2 after challenge, further amplifi cation of this response by inclusion of a dose of IPV in the immunisation regimen (ie, in the bOPV-IPV group) did not further reduce virus recovery. Restriction of virus shedding after mOPV type 2 challenge was linked to previous receipt of homotypic OPV (tOPV). Additionally, little if any immunity to type 2 mOPV was induced by receipt of heterotypic bOPV. Although unlikely, resistance to mOPV type 2 challenge could be due to induction of some other type of protective immunity unrelated or additional to the observed mucosal and serum neutralisation responses. Because the number of infants in the tOPV group who shed virus after challenge was quite small, we were unable to rigorously implicate mucosal antibody as the key protective factor within that group. In general, discerning the relative contribution of mucosal or serum neutralisation responses to the recorded restriction of virus shedding was complicated by the limited number of infants shedding virus after immunisation with tOPV; confounding serum and mucosal antibody responses that were not attributable to vaccine receipt in the trial and were noted in infants from all groups; and a general concordance of the mucosal and serum neutralising responses after immunisation with tOPV. Furthermore, we conclude that serum neutralising antibody, the traditional measure of vaccine-induced immunity, is a limited determinant of virus replication in the intestinal tract. This observation is crucial to decisions about future approaches to elimination of poliovirus circulation and sustainment of a polio-free world. The experience in Israel, where sustained circulation of wildtype polio occurred in a population highly immunised with IPV, 20 provides further evidence of the importance of adopting an endgame vaccine regimen for the interim that also induces mucosal immunity.
Together with our preceding study, 18 in this study we establish a unique method to measure strain-specifi c mucosal antibody responses to poliovirus that reveals functionality (virus neutralisation) at very high titres (often ≥512) equivalent to those measured in serum. Previous attempts to measure mucosal immunity have largely focused on measurements of binding antibody, primarily of the IgA class. Luminex provides a state-ofthe-art platform for polio-specifi c IgA determination. Substantial diffi culties have also been encountered in development of reproducible assays to assess virus neutralisation mediated by respiratory, genital, or enteric specimens. Aside from the recognised complications of sample variability during collection, processing, and assaying, measurement of functional activity in biological assays is fraught with challenges associated with cellular toxicity or cell culture contamination by the specimen, or both. Most of these shortcomings are subverted by the rapid readout of the polio pseudovirus assay, which provides a sensitive and reproducible means of assessing neutralisation after a single cycle of virus replication. 18 Several questions remain unanswered. First, what is the origin of the serum and mucosal neutralising responses seen in the bOPV group before OPV type 2 challenge, which theoretically had not yet received any type 2 vaccine? Serum responses could indicate residual maternal antibody or antibody acquired during intercurrent infection, although eff orts were made to avoid any secondary exposure to vaccine virus in the family setting. Mucosal antibody responses might also refl ect variation in sample collection, storage, or residual maternal breast milk antibody. Second, what mediates the early neutralising response noted on challenge? IgA is assumed to be the major mediator of mucosal immunity. 21 If so, why was there not a better correlation between the height of mucosal neutralisation and IgA concentrations at challenge and the amount of virus shedding 1 week later? In determining virus titre, the samples were frozen on collection and treated with chloroform immediately after thawing. We have shown that chloroform rapidly inactivates antibody. Thus neutralisation has little opportunity to occur in the limited timeframe between evacuation and sample processing. With respiratory syncytial virus, mucosal antibody was found bound to cell-associated virus in secretions and only later were investigators able to detect free antibody. 22 The poorly defi ned site or sites of replication of poliovirus in the enteric tract (eg, Peyer's patches) could make the virus inaccessible to antibody secreted into the intestinal lumen. 23 Furthermore, we would conclude that the induction of immunity noted 1 week after challenge is not necessarily indicative of priming, because it was reported in children who were undergoing their initial exposure to type 2 vaccine. Finally, the duration of mucosal immunity is unknown, but we suspect it to be shorter than that of serum antibody, and thus the protection recorded almost certainly will wane. 24 In this study, we could not address duration or the concept that previous OPV mucosal immunity is boosted by IPV. 25 In summary, another tool has been added to assessments of immunity after receipt of polio vaccines. Our fi ndings move beyond the initial observation that OPV is a much better mucosal immunogen than IPV, as evidenced by greater inhibition of virus replication upon challenge, and show a mechanism by which this anti- viral activity might occur. In defi ning a mechanism for measuring mucosal immunity for polio, there is a mandate to extend these observations and apply these fi ndings to other live virus vaccines that are either in clinical use (eg, infl uenza, rotavirus) or actively under development (eg, respiratory syncytial virus).
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